Bifogade filer
Kurs
+0,76%
Likviditet
0,01 MSEK
Kalender
Est. tid* | ||
2025-05-28 | 08:10 | Kvartalsrapport 2025-Q1 |
2025-04-09 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2025-04-08 | - | Årsstämma |
2025-02-14 | - | Bokslutskommuniké 2024 |
2024-11-29 | - | Kvartalsrapport 2024-Q3 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-07-08 | - | Split APTA 100:1 |
2024-06-19 | - | Extra Bolagsstämma 2024 |
2024-05-31 | - | Kvartalsrapport 2024-Q1 |
2024-05-17 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2024-05-15 | - | Årsstämma |
2024-02-29 | - | Bokslutskommuniké 2023 |
2024-01-09 | - | Extra Bolagsstämma 2023 |
2023-10-30 | - | Kvartalsrapport 2023-Q3 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-06-02 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2023-06-01 | - | Årsstämma |
2023-05-11 | - | Kvartalsrapport 2023-Q1 |
2023-02-15 | - | Bokslutskommuniké 2022 |
2022-11-08 | - | Kvartalsrapport 2022-Q3 |
2022-08-25 | - | Kvartalsrapport 2022-Q2 |
2022-06-03 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2022-06-02 | - | Årsstämma |
2022-05-19 | - | Kvartalsrapport 2022-Q1 |
2022-02-10 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-06-03 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2021-06-02 | - | Årsstämma |
2021-05-20 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-30 | - | Kvartalsrapport 2020-Q3 |
2020-09-25 | - | Extra Bolagsstämma 2020 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-06-04 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2020-06-03 | - | Årsstämma |
2020-05-14 | - | Kvartalsrapport 2020-Q1 |
2020-02-12 | - | Bokslutskommuniké 2019 |
2019-10-24 | - | Kvartalsrapport 2019-Q3 |
2019-08-28 | - | Kvartalsrapport 2019-Q2 |
2019-06-12 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2019-06-11 | - | Årsstämma |
2019-05-15 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-08-29 | - | Kvartalsrapport 2018-Q2 |
2018-06-07 | - | Extra Bolagsstämma 2018 |
2018-05-07 | - | Årsstämma |
2018-05-07 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-11-15 | - | Kvartalsrapport 2017-Q3 |
2017-09-11 | - | Extra Bolagsstämma 2017 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-06-08 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2017-06-07 | - | Årsstämma |
2017-05-18 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-10-27 | - | Kvartalsrapport 2016-Q3 |
2016-08-20 | - | Kvartalsrapport 2016-Q2 |
2016-06-09 | - | Årsstämma |
2016-05-19 | - | X-dag ordinarie utdelning APTA 0.00 SEK |
2016-05-18 | - | Kvartalsrapport 2016-Q1 |
2016-03-22 | - | Extra Bolagsstämma 2016 |
2016-02-18 | - | Bokslutskommuniké 2015 |
2015-10-29 | - | Kvartalsrapport 2015-Q3 |
2015-08-20 | - | Kvartalsrapport 2015-Q2 |
2015-05-18 | - | Årsstämma |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
Aptahem's nomination committee for the AGM next year has held a meeting. The nomination committee consists of three members represententing the three largest owners as of 30 September this year that wish to appoint a representative to the committee as well as one appointed board member as convener.
Members of the nomination committee for the AGM 2023 consists of Ivar Nordqvist, chairman of the committee, Christian Pettersson, Tina Persson together with Bert Junno, chairman of the board at Aptahem.
The nomination committee is tasked with making proposals for the chairman of the meeting, election of board members and board fees, election for auditor and auditor's fee and, to the extent deemed necessary, changes to the instructions for the nomination committee.
Shareholders who wish to submit proposals to the nomination committee can do so in writing to valberedning@aptahem.comor to the following address:
Att: Valberedningen
Aptahem AB
Norra Vallgatan 58
211 22 Malmö
The nomination committee's proposal will be presented in the notice to the annual general meeting and on the company's website.
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.